Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198998 | 1.00 | HIF1A (0.56) | HIF1AEGFRERBB2ADA | |
| SCHEMBL4745554 | 0.87 | EGFR (0.61) | HIF1AEGFRERBB2ADA | |
| SCHEMBL21133221 | 0.87 | EGFR (0.61) | HIF1AEGFRERBB2ADA | |
| SCHEMBL27272946 | 0.87 | EGFR (0.61) | HIF1AEGFRERBB2ADA | |
| SCHEMBL4745556 | 0.87 | EGFR (0.61) | HIF1AEGFRERBB2ADA | |
| Deoxyinosine SCHEMBL324457 | 0.86 | HIF1A (0.73) | HIF1A | |
| Deoxyinosine SCHEMBL7191121 | 0.86 | HIF1A (0.73) | HIF1A | |
| Deoxyinosine SCHEMBL2000526 | 0.86 | HIF1A (0.73) | HIF1A | |
| Deoxyinosine SCHEMBL24307 | 0.86 | HIF1A (0.73) | HIF1A | |
| Deoxyinosine SCHEMBL5982293 | 0.86 | HIF1A (0.73) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1816135-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | Ajinomoto Co., Inc. (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | AJINOMOTO CO. INC. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-5571798-A | TREATMENT OF RETROVIRUS WITH 3-FLUORO-3'-DEOXYTHYMIDINE AND AZIDO DERIVATIVES | MEDIVIR AB (SE) | 1996-11-05 | — | — | US | disclosed |
| EP-0482081-B1 | ANTIVIRAL COMPOSITION | OEBERG BO (SE) | 1996-01-10 | — | — | EP | disclosed |
| EP-0371366-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | PNP, NUDT1, ADAR | HIF1A 2172/4885EGFR 4744/4885ERBB2 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.